Compare · MRK vs PBH
MRK vs PBH
Side-by-side comparison of Merck & Company Inc. (MRK) and Prestige Consumer Healthcare Inc. (PBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PBH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $298.33B, about 133.5x PBH ($2.24B).
- MRK has been more active in the news (26 items in the past 4 weeks vs 1 for PBH).
- MRK has more recent analyst coverage (25 ratings vs 12 for PBH).
- Company
- Merck & Company Inc.
- Prestige Consumer Healthcare Inc.
- Price
- $120.22-0.55%
- $47.52+0.74%
- Market cap
- $298.33B
- $2.24B
- 1M return
- +7.15%
- -
- 1Y return
- +51.75%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2005
- News (4w)
- 26
- 1
- Recent ratings
- 25
- 12
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Latest MRK
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
- SEC Form 4 filed by Director Lavizzo-Mourey Risa J
Latest PBH
- Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
- SEC Form 10-K filed by Prestige Consumer Healthcare Inc.
- Amendment: CFO & COO Sacco Christine covered exercise/tax liability with 1,091 shares, decreasing direct ownership by 2% to 57,374 units (SEC Form 4)
- Prestige Consumer downgraded by Oppenheimer
- Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
- Senior VP Operations Zerillo Jeffrey sold $18,350 worth of shares (351 units at $52.28), decreasing direct ownership by 0.83% to 41,810 units (SEC Form 4)
- Senior VP Operations Zerillo Jeffrey sold $16,580 worth of shares (305 units at $54.36) and covered exercise/tax liability with 351 shares, decreasing direct ownership by 2% to 42,161 units (SEC Form 4)
- CFO & COO Sacco Christine covered exercise/tax liability with 991 shares, decreasing direct ownership by 1% to 71,636 units (SEC Form 4)
- Chief Executive Officer Lombardi Ronald M. covered exercise/tax liability with 2,543 shares, decreasing direct ownership by 0.68% to 373,465 units (SEC Form 4)